Clinical trial
Study Investigating Enbrel Treatment for Ankylosing Spondylitis
NCT00195416 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195416 |
|---|---|
| Title | Study Investigating Enbrel Treatment for Ankylosing Spondylitis |
| Official title | A Drug Use Investigation of Enbrel for Post-marketing Surveillance (PMS) for Ankylosing Spondylitis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Ankylosing Spondylitis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 526 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Sep 16, 2009 |
| Countries | South Korea |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: